PCN32 Panitumumab + Mfolfox6 Versus Bevacizumab + Mfolfox6 As First-Line Treatment of Wild-Type Ras Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis from the Brazilian Private Healthcare System Perspective
| Autor: | dos Santos, RF, Coutinho, MB, Haas, L |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Value in Health. (7):A821 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2015.09.260 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|